JP2004517824A5 - - Google Patents

Download PDF

Info

Publication number
JP2004517824A5
JP2004517824A5 JP2002544060A JP2002544060A JP2004517824A5 JP 2004517824 A5 JP2004517824 A5 JP 2004517824A5 JP 2002544060 A JP2002544060 A JP 2002544060A JP 2002544060 A JP2002544060 A JP 2002544060A JP 2004517824 A5 JP2004517824 A5 JP 2004517824A5
Authority
JP
Japan
Prior art keywords
kit according
repinotan
concentration
measuring
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002544060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517824A (ja
Filing date
Publication date
Priority claimed from DE10058119A external-priority patent/DE10058119A1/de
Application filed filed Critical
Publication of JP2004517824A publication Critical patent/JP2004517824A/ja
Publication of JP2004517824A5 publication Critical patent/JP2004517824A5/ja
Pending legal-status Critical Current

Links

JP2002544060A 2000-11-22 2001-11-09 レピノタンのキット Pending JP2004517824A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10058119A DE10058119A1 (de) 2000-11-22 2000-11-22 Pepinotan-Kit
PCT/EP2001/012968 WO2002041881A2 (de) 2000-11-22 2001-11-09 Repinotan-kit

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005128270A Division JP2005232189A (ja) 2000-11-22 2005-04-26 神経変性疾患の緊急処置のためのレピノタン

Publications (2)

Publication Number Publication Date
JP2004517824A JP2004517824A (ja) 2004-06-17
JP2004517824A5 true JP2004517824A5 (enExample) 2005-12-22

Family

ID=7664358

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002544060A Pending JP2004517824A (ja) 2000-11-22 2001-11-09 レピノタンのキット
JP2005128270A Pending JP2005232189A (ja) 2000-11-22 2005-04-26 神経変性疾患の緊急処置のためのレピノタン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005128270A Pending JP2005232189A (ja) 2000-11-22 2005-04-26 神経変性疾患の緊急処置のためのレピノタン

Country Status (37)

Country Link
US (2) US6605255B2 (enExample)
EP (1) EP1339403B1 (enExample)
JP (2) JP2004517824A (enExample)
KR (1) KR20030096237A (enExample)
CN (2) CN1518446A (enExample)
AR (1) AR031761A1 (enExample)
AT (1) ATE284212T1 (enExample)
AU (1) AU2002227912A1 (enExample)
BG (1) BG107803A (enExample)
BR (1) BR0115518A (enExample)
CA (1) CA2429310A1 (enExample)
CZ (1) CZ20031401A3 (enExample)
DE (2) DE10058119A1 (enExample)
DO (1) DOP2001000293A (enExample)
EC (1) ECSP034617A (enExample)
EE (1) EE200300242A (enExample)
ES (1) ES2234922T3 (enExample)
GT (1) GT200100236A (enExample)
HN (1) HN2001000262A (enExample)
HR (1) HRP20030490A2 (enExample)
HU (1) HUP0303294A2 (enExample)
IL (1) IL155975A0 (enExample)
MA (1) MA26059A1 (enExample)
MX (1) MXPA03004499A (enExample)
MY (1) MY118345A (enExample)
NO (1) NO20032212D0 (enExample)
NZ (1) NZ525964A (enExample)
PE (1) PE20020533A1 (enExample)
PL (1) PL361628A1 (enExample)
PT (1) PT1339403E (enExample)
RU (1) RU2003118583A (enExample)
SI (1) SI1339403T1 (enExample)
SK (1) SK5922003A3 (enExample)
SV (1) SV2003000744A (enExample)
UY (1) UY27027A1 (enExample)
WO (1) WO2002041881A2 (enExample)
ZA (1) ZA200303888B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE19522088A1 (de) * 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19543476A1 (de) * 1995-11-22 1997-05-28 Troponwerke Gmbh & Co Kg Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE19754573A1 (de) * 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
EP1062510A2 (en) * 1998-03-10 2000-12-27 Strategic Diagnostics Inc. Integrated assay device and methods of production and use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19936281C2 (de) 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung

Similar Documents

Publication Publication Date Title
JP2004517824A5 (enExample)
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
EP1651195A4 (en) PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2002093173A3 (de) Screeningverfahren mit pim1-kinase oder pim3-kinase
EP1692305A4 (en) DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
JP6395774B2 (ja) 水素ガスからなる認識機能低下抑制剤
EP1491210A4 (en) THERAPEUTIC MEDICAMENT USING ANTIBODY PRESENTING HOLES PROTEIN NANOTEHICLES AND HIGH PROTEIN NANOTEHICLES
EP1532162A4 (en) HUMANIZED ANTI-DAY-72 CC49 FOR DIAGNOSIS AND THERAPY HUMAN TUMORS
WO2003000733A3 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.
ES2036661T3 (es) Un metodo para preparar una preparacion farmaceutica de pie de atleta.
RU2003118497A (ru) Способ лечения заболеваний слизистых оболочек
EP1669085A4 (en) MEDICAL AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER
DE60234031D1 (de) Mittel zur behandlung allergischer augenerkrankungen
RU98118517A (ru) Способ профилактики и лечения экологически зависимого синдрома поражения крови у детей
JP2004530642A5 (enExample)
EP1644483A4 (en) USE OF PLEIOTROPHINE IN THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES
FR2855056B1 (fr) Medicament notamment pour le traitement de la drepanocytose ou du sida
SI1474415T1 (sl) 1-fenil-2-heteroaril-substituirani derivati benzimidazola, njihova uporaba za izdelavo zdravil za zdravljenje imunoloških bolezni
AU2002240745A1 (en) Diagnosis and treatment of blood disorders
EP1395227A4 (en) METHOD AND COMPOUNDS FOR DIAGNOSIS OF INFLAMMATORY DISEASES AND IDENTIFICATION OF PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES